Lunning and Herrera Highlight Frontline Hodgkin Lymphoma Management Strategies

The Blood Club, hosted by Matthew Lunning, DO, FACP, is a podcast that seeks to translate the latest hematologic oncology research findings into practical clinical implications for the treatment of patients with hematologic malignancies. Dr Lunning is an associate professor in the Division of Oncology & Hematology, associate vice chair of research in the Department of Internal Medicine, and assistant vice chancellor of clinical research at the University of Nebraska Medical Center in Omaha.

In this episode, Dr Lunning sat down with Alex Herrera, MD, to discuss the frontline management of Hodgkin lymphoma. Dr Herrera is an associate professor in and chief of the Division of Lymphoma in the Department of Hematology & Hematopoietic Cell Transplantation, as well as the associate medical director of the Briskin Center for Clinical Research at City of Hope in Duarte, California.

Drs Lunning and Brander highlighted the rationale for and potential implications of the phase 3 SWOG 1826 trial (NCT03907488) of nivolumab (Opdivo) or brentuximab vedotin (Adcetris) plus combination chemotherapy in patients with newly diagnosed classic Hodgkin lymphoma, the collaborative efforts between pediatric and adult oncologists that led to the successful initiation of this trial, potential future directions for this research, and more.